Borg, Christophe <br/><br/>
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.  [electronic resource] 

 -  Clinical colorectal cancer  09 2019 
 - 200-208.e1 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0674 
<br/><br/><label>Standard No.: </label>10.1016/j.clcc.2019.04.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Capecitabine--administration & dosage<br/>Chemoradiotherapy, Adjuvant<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Leucovorin--administration & dosage<br/>Lymphatic Metastasis<br/>Magnetic Resonance Imaging--methods<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Oxaliplatin--administration & dosage<br/>Rectal Neoplasms--drug therapy<br/>Survival Rate<br/>Young Adult